Registro de fonte primária
Nível de decisãoResultados topline
Cartesian relata 100% de resposta LLDAS no estudo de Fase 2 de Descartes-08 em lúpus (SLE)
Phase 2 open-label data show 100% LLDAS response and 2/3 DORIS remission at Month 3 in refractory SLE patients treated with outpatient Descartes-08. The company will pause further SLE development to prioritize myasthenia gravis (Phase 3) and myositis (Phase 2 trial planned to start 1H26).
Fatos principais
- Arquivado
- 13 de nov. de 2025, 21:08
- Evento
- Resultados topline
- Direção
- Positivo
- Empresa
RNACCartesian Therapeutics- Ativo
- Descartes-08
- Fonte
- SEC 8-K
- Confiança
- Com fonte
- valor p
- p<0.01
- remissão DORIS
- 2/3
- taxa de resposta LLDAS
- 100% (3/3)
- início do ensaio de miosite
- 1S26
Trecho da fonte
EX-99.1 2 pressrelease11132025.htm EX-99.1 Document Exhibit 99.1 Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis 100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) Disease remission reported as DORIS response seen in 2 out of 3 patients reaching Month 3 follow-up (n=3) Descartes-08 in SLE patients was observed to have a favorable safety profile supporting outpatient administration without the need for lymphodepleting chemotherapy Myositis seamless adaptive clinical trial design provides potential opportunity for a single pivotal trial expected to commence in 1H26 FREDERICK, Md., Nov. 1